11,000 people are predicted to die from acute myeloid leukemia (AML) in 2019. Recently, drug developers designed a new treatment to target the cancer’s mutated genes. But, these drugs don’t always work. Now, in a new study, researchers investigate both sides of the drug-body relationship to better understand why certain AML treatments — and other cancer treatments — may not work as expected.